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Abstract
Combined activation of Ras and Akt leads to the
formation of astrocytic glioblastoma multiforme (GBM)
in mice. In human GBMs, AKT is not mutated but is
activated in approximately 70% of these tumors, in
association with loss of PTEN and/or activation of
receptor tyrosine kinases. Mechanistic justification for
the therapeutic blockade of targets downstream of
AKT, such as mTOR, in these cancers requires
demonstration that the oncogenic effect of PTEN loss
is through elevated AKT activity. We demonstrate here
that loss of Pten is similar to Akt activation in the
context of glioma formation in mice. We further
delineate the role of mTOR activity downstream of
Akt in the maintenance of Akt+KRas–induced GBMs.
Blockade of mTOR results in regional apoptosis in
these tumors and conversion in the character of
surviving tumor cells from astrocytoma to oligoden-
droglioma. These data suggest that mTOR activity is
required for the survival of some cells within these
GBMs, and mTOR appears required for the mainte-
nance of astrocytic character in the surviving cells.
Furthermore, our study provides the first example of
conversion between two distinct tumor types usually
thought of as belonging to specific lineages, and
provides evidence for signal transduction–mediated
transdifferentiation between glioma subtypes.
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Introduction
Glioblastoma multiforme (GBM) is the most frequent and
malignant glioma. Disruption of the cell cycle arrest path-
way is common and usually achieved by loss of INK4a-ARF
in these tumors [1]. In addition, overexpression or gain-of-
function mutations of receptor tyrosine kinases, such as
epidermal growth factor receptor (EGFR), platelet-derived
growth factor receptor (PDGFR), and fibroblast growth
factor receptor (FGFR) are frequent [2–5], leading to
constitutive activation of RAS/MAPK, PI3K/AKT, and other
signal transduction pathways. Indeed, the activity of RAS
is elevated in the vast majority of GBMs [6], and the activity of
AKT is elevated in a majority of the examined GBMs [7,8].
Although no activating mutations in the AKT gene are seen in
GBMs, AKT is associated with loss of function of PTEN
(phosphatase and tensin homology deleted on chromosome
10). Approximately 50% to 70% of GBMs have PTEN deletion,
mutation, or loss of PTEN expression, implicating PTEN as one
of the most affected genes in this disease [9–11].
PTEN is mutated or deleted in a large variety of cancers,
including GBMs, endometrial cancer, and prostate cancer, and
has been well recognized as a tumor suppressor [12–15].
PTEN is a lipid phosphatase as well as a protein phosphatase,
and the lipid phosphatase activity is essential for its function
as a tumor suppressor [16]. PTEN antagonizes the function of
phosphoinositide 3-kinase (PI3K) by dephosphorylating phos-
phatidylinositol 3,4,5-triphosphate [PtdIns(3,4,5)P3] at the D3
position [17]. PtdIns(3,4,5)P3 facilitates the translocation of
AKT to the plasma membrane. PtdIns(3,4,5)P3 also activates
PDK1, which then phosphorylates and activates AKT [18–20].
Thus, loss of PTEN function leads to increased AKT activity.
AKT activity promotes cell survival and proliferation through
phosphorylation and inactivation of Bad, GSK-3b, FOXO, IKK,
and caspase 9 [21]. AKT also activates the mammalian target
of rapamycin (mTOR) through TSC1/2 and Rheb [22,23], which
in turn phosphorylate p70 S6 kinase (S6K1) and 4E-BP1 [24]—
two key regulators for protein synthesis. Phosphorylation of
S6 ribosomal protein by S6K1 has been proposed to increase
the translation of a group of mRNA containing an oligopyrimi-
dine tract at their 5V termini (5V TOP), which encode ribosomal
proteins and elongation factors [25]. Phospho-4E-BP1 disso-
ciates from the complex with the translational initiation fac-
tor eIF4E, and the free eIF4E can enhance cap-dependent
translation [26]. In mouse glia, Akt activity cooperates with
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Ras to specifically recruit existing mRNA encoding growth-
promoting proteins to ribosomes [27].
Several studies have suggested a linear oncogenic path-
way of PTEN/AKT/mTOR. First, PTEN/ tumors have
higher AKT and mTOR activity. Second, the mTOR inhibitor,
rapamycin, reduces tumor cell proliferation and tumor
growth, but has no effect on PTEN+/+ tumors, suggesting
that mTOR is responsible for the oncogenic effect of PTEN
loss [28,29]. In addition, mTOR is required for cell transfor-
mation by PI3K and AKT [30]. Moreover, in human GBMs,
mTOR activity correlates with AKT activity [31,27], raising
the possibility that the oncogenic effect of AKT might be
achieved through mTOR.
We previously reported that the somatic cell gene
transfer by the RCAS/tv-a modeling system of constitu-
tively activated Akt and KRas cooperatively induces GBMs
from neural progenitors, but not from differentiated astro-
cytes [8]. In addition to its oncogenic effect, Akt activation
in glial tumors also leads to astrocytic differentiation [32,33].
In human GBMs, PTEN mutation or deletion is very com-
mon, but no activating mutations of AKT have been found.
It remains to be determined whether PTEN loss alone is
sufficient to achieve the oncogenic effect of activated AKT
in GBM formation. Besides AKT, loss of PTEN function
activates other factors such as SHC and FAK [34–36].
Whether activated AKT fully recapitulates the oncogenic
function of PTEN loss is unknown. If PTEN loss is equiv-
alent to activated AKT in tumorigenesis, therapeutic target-
ing of molecules downstream of AKT in PTEN-null GBMs
would be justified; if PTEN loss is insufficient to achieve
the oncogenic effect of AKT, anti-receptor tyrosine kinase
therapy might be necessary for those tumors. Because
homozygous Pten deletion in mice results in embryonic
lethality, we addressed this question by conditional target-
ing of Pten in glia with the combination of RCAS/tv-a and
Cre/Lox systems.
mTOR has been proposed to be an important factor in
the signaling downstream of AKT; we therefore investigated
whether its activity is elevated and required for the mainte-
nance of Akt+KRas–induced GBMs by blocking mTOR with
a rapamycin analog, CCI-779. The CCI-779 treatment of
mouse GBMs results in two effects. A subset of tumor cells
with elevated Akt undergo apoptosis on mTOR blockade,
indicating that mTOR activity is required for survival of those
tumor cells. Furthermore, the surviving tumor cells convert
their astrocytic character to oligodendroglial morphology,
suggesting that mTOR is also required to maintain astrocytic
character in these GBMs.
Results
Generation of Conditional Glia-Specific Pten Mutant Mice
Mouse mutants in which Pten exons 4 and 5 are
flanked by LoxP sites have been described before [37].
tv-a mice expressing tv-a in neural progenitors (Ntv-a) [38]
or predominantly in astrocytes (Gtv-a) [39] were crossed
with the PtenloxP/loxP (LP) mice, and the homozygous tv-a
PtenloxP/loxP (Ntv-a LP; Gtv-a LP) mice were obtained. The
Cre recombinase fused with the green fluorescent protein
(GFP) encoded by the RCAS vector allows recombination
between the LoxP sites in progenitors or astrocytes,
leading to Pten deletion in those cells.
To test whether this strategy works, primary brain cells
from Ntv-a LP mice were infected with RCAS-Cre or control
RCAS-LacZ virus. Due to the heterogeneity of the cell
population and infection efficiency, only some of the neural
progenitors were infected by the RCAS virus. Subsequently,
polymerase chain reaction (PCR) analysis showed that Cre
specifically catalyzed recombination and Pten deletion in
the infected progenitors, whereas the Pten gene in other
types of cells and the uninfected neural progenitors remained
intact (Figure 1B).
Loss of Pten in Cultured Neural Progenitors Activates Akt,
But Does Not Activate MAPK Pathway
We next studied the consequence of Pten loss in glial cell
culture. We observed that Cre decreased Pten protein level
and activated Akt to a similar level as that of RCAS-Akt–
infected primary brain cells cultured in mediumwith 10% fetal
bovine serum (FBS) fromNtv-a LPmice (data not shown). To
avoid PI3K/Akt activation by growth factors in the serum,
primary brain cells from Ntv-a LP mice infected with the
RCAS viruses were cultured in serum-free medium for
24 hours. Western blot analysis showed that Cre led to a
significant reduction in Pten levels and the consequent
increase in phospho-Akt (P-Akt) similar to cells infected with
the RCAS-Akt virus that encodes a constitutively active Akt.
This observation implies that loss of Pten alone is sufficient
to achieve a high level of activated Akt in cultured progen-
itors. Cre itself did not change Pten expression or Akt activity
in primary brain cells fromNtv-awild-type (wt) mice. Total Akt
protein levels decreased in cells infected with RCAS-Akt,
RCAS-Cre, RCAS-Akt+RCAS-KRas, and RCAS-Cre+RCAS-
KRas, suggesting that elevated Akt activity in those cells
exerted a negative feedback on Akt protein levels. This is
consistent with a previous finding stating that, in human
GBMs, elevated AKT activity correlates with decreased total
AKT protein levels [8]. Cre-induced Pten deletion did not
result in activation of Erk, suggesting that loss of Pten did not
activate the MAPK pathway in progenitors. Elevated Ras
activity achieved by RCAS-KRas infection did not activate
PI3K/Akt pathway as measured by P-Akt levels. However,
KRas, in combination with Akt or Cre, led to activation of both
MAPK and PI3K/Akt pathways (Figure 1C ).
Loss of Pten Cooperates with KRas Activation to Induce
GBMs from Neural Progenitors
Our previous work demonstrated that the combination of
KRas and Akt induces GBMs from neural progenitors with an
incidence of 21.3% [8,32]. To investigate the function of Pten
loss in tumorigenesis, 37 newborn Ntv-a LP mice were
injected intracranially with a combination of cells producing
RCAS-KRas and RCAS-Cre. All the mice were sacrificed at
12 weeks of age, or earlier if they showed signs or symptoms
of macrocephaly and lethargy. The mouse brains were
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fixed and the sections were stained with hematoxylin and
eosin (H&E).
Of the 37 Ntv-a LP mice, 23 (62.2%) developed paren-
chymal lesions that varied in size. Histologically, these
lesions showed increased cell density, pseudopalisading
necrosis, microvascular proliferation, and nuclear pleiomor-
phism that looked similar to KRas+Akt–induced GBMs in
Ntv-a wt mice (Figure 2A). Immunohistochemical staining
(IHC) analysis demonstrated that Pten was absent in the
tumor cells but present in the surrounding normal brain cells
and endothelial cells within the tumors (higher magnification
not shown). The tumor cells stained positive for phospho-
Erk, indicating that they were infected by RCAS-KRas. They
were proliferating, as shown by positive staining for prolifer-
ating cell nuclear antigen (PCNA), and they also expressed
nestin and glial fibrillary acid protein, indicating their glial
origin (Figure 2B). Some of the tumors are strongly positive
for GFAP (Figure 2C)—one characteristic of human GBMs.
A finding consistently associated with both KRas+Akt and
KRas+Pten loss tumors of all sizes was a conspicuous
inflammatory element including perivascular infiltration by
small lymphocytes and parenchymal histocytic infiltrates that
virtually obscured the neoplastic component of some early
evolving lesions. GFAP and nestin expression on the part of
atypical cells revealed neoplastic populations in some small
lesions accompanied by florid lymphohistocytic responses.
To what extent this observation in mice represents the char-
acteristics of early high-grade human gliomas is not known.
We determined whether loss of Pten alone is sufficient to
cause GBMs by infecting 32 Ntv-a LP mice with RCAS-Cre
and found that no tumors arose. This result is similar to our
earlier studies that Akt alone is insufficient to induce GBMs
[8]. RCAS-mediated gene transfer of KRas and Cre did not
result in GBM formation inGtv-a LPmice (n = 23), consistent
with the observation that the combination of KRas and Akt is
unable to induce GBMs in Gtv-a wt mice [8]. Cre has been
shown to cause chromosomal aberrations, which may po-
tentially increase tumor susceptibility [40]. We thus infected
19 Ntv-a wtmice with RCAS-KRas and RCAS-Cre to test the
specificity of the recombination at the Pten locus. None of
these mice developed tumors, suggesting that it is the Cre-
induced Pten deletion that contributes to tumor formation
(Figure 3A). However, the genetic backgrounds of Ntv-a wt
and Ntv-a LPmice were different, which could affect the size
or number of tumors induced by KRas and Akt.
Therefore, to compare the function of Pten loss and
activated Akt in the same genetic background, 37 newborn
Ntv-a LP mice were infected with RCAS-KRas and RCAS-
Akt. Eighteen mice (48.6%) developed GBMs, which were
histologically indistinguishable from KRas+Pten–null tumors
(Figure 3B). The tumor incidences of these two groups of
mice were not statistically different (P = .61).
We previously generated GBMs with the combination
KRas and Akt inNtv-a wtmice [8,32], and there was a certain
percentage of large-sized and medium-sized tumors. In
contrast, we observed that most tumors induced in Ntv-a
LPmice by KRas and Pten-null or KRas and Akt were small,
and the distribution pattern of these GBMs differs from
KRas+Akt–induced GBMs in Ntv-a wt mice (Figure 3, C
and D). In addition, the tumor incidences of Ntv-a LP mice
were statistically higher than that of Ntv-a wt mice (P < .01;
Figure 3D). Therefore, it appears that the genetic background
Figure 1. Combined RCAS/tv-a and Cre/Lox systems result in Pten deletion
and consequent Akt, but not MAPK pathway activation. (A) Schematic
representation of the location of PCR primers to detect the wild-type (wt),
floxed, and recombined Pten allele. (B) PCR analysis indicates that RCAS-
Cre resulted in Pten deletion in some of the neural progenitors (lane 1, upper
band) from Ntv-a LP mice, but not in other types of primary brain cells or
uninfected neural progenitors (lane 1, lower band). DNA of RCAS-LacZ–
infected primary Ntv-a LP brain cells (lane 2), tail DNA from Ntv-a LP+/
(lane 3), and dH2O (lane 4) were used as controls. (C) Western blot analysis
shows that Cre decreased Pten protein level and consequently activated the
Akt pathway, but not the MAPK pathway, in neuronal progenitors from Ntv-a
LP mice. GAPDH was used as a loading control.
Supplementary Figure 1. Low-power views (100) of GFAP/Olig2 staining in
the untreated and 7-day– treated mouse GBMs. In contrast to the IHC of
GFAP in the untreated tumors (A), the pattern of GFAP staining in the 7-day–
treated tumors was similar to that in oligodendrogliomas, and GFAP-positive
cells were reactive astrocytes. In the untreated tumors, Olig2 staining was very
heterogeneous. There was no Olig2-positive cells in approximately 90% of
microscopic views (B), and (C) represents a view with maximumOlig2-positive
cells. (E) and (F) show that almost all surviving tumor cells in two treated
tumors were Olig2-positive, and that Olig-2 negative cells were reactive with
astrocytes and vascular cells. The asterisks in (F) indicate areas of necrosis.
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of Ntv-a LP mice made them more susceptible to tumor
initiation but less to tumor progression.
Activated Akt alone is unable to induce GBMs in Ntv-a
Ink4a-Arf/ mice [32]. To further investigate the similarities
of Pten loss and Akt activation, we determined whether loss
of Ink4a-Arf and Pten cooperates to form GBM. We infected
27 Ntv-a Ink4a-Arf/ LP mice with RCAS-Cre and found
that no tumors developed, indicating that loss of combined
Ink4a-Arf and Pten is insufficient for tumor formation. In
summary, the above data suggest that Pten loss and acti-
vated Akt function similarly in tumorigenesis.
mTOR Activity Correlates with Activated Akt in Akt+KRas–
Induced GBMs
mTOR has been proposed to be an important component
downstream of the Akt signaling pathway. We therefore
initially tested whether the phospho levels of S6 downstream
of mTOR correlate with Akt activity in the KRas+Akt–
induced tumors from Ntv-a wt mice. As the RCAS-encoded
constitutively active Akt construct contains an HA tag se-
quence, detection of HA represents the retroviral expression
of the activated Akt. The tumors were immunostained
with an anti-HA antibody, and the adjacent sections were
Figure 2. Histologic analysis of GBMs induced by Cre+KRas from Ntv-a LP mice (A) H&E–stained sections illustrates increased cell density, pseudopalisading
necrosis (asterisk), microvascular proliferation, and nuclear polymorphism (arrow) (original magnification of pictures on the upper panel and lower left panel, 40;
original magnification of the picture on the lower right panel, 400). (B) (40) IHC shows that Pten was absent in the tumor cells but present in the normal brain
cells and endothelial cells within the tumors (higher magnification not shown). The tumor cells were positive for P-Erk and PCNA, and some of them were positive
for GFAP and nestin. (C) (50) IHC shows that some GBMs stained strongly positive for GFAP—one of the characteristics of human GBMs.
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Figure 3. Loss of Pten is similar to activated Akt in gliomagenesis. (A) Percent GBM-free mice curves indicate that Cre+KRas and Akt+KRas induced GBMs from
Ntv-a LP (nestin-expressing neuronal progenitors) with no significant difference in tumor incidence (62.2% vs 48.6%; P = .61). (B) (10) H&E comparison of the
GBMs induced by Cre+KRas and Akt+KRas from Ntv-a LP mice shows similar tumor morphology. (C) (10) In Ntv-a wt background, Akt+KRas resulted in large
(L), medium (M), and small (S) GBMs; whereas in Ntv-a LP background, Cre+KRas led to only one medium-sized GBM and most GBMs were small. (D) Tumor
incidence was higher in Ntv-a LP mice compared to Ntv-a wt mice (P < .01). (E) Percentage of large-sized and medium-sized tumors was higher in Ntv-a wt mice.
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immunostained with an antibody against phospho-S6 (P-S6).
Within these tumors, there was regional variation in HA
staining, implying that Akt activity was also regionally vari-
able. The tumor cells positive for HA were also positive for
P-S6 (Figure 4, A, B, E, and F ), suggesting that mTOR
pathway is upregulated and that it correlates with activated
Akt in this mouse GBM model.
Treatment of GBM-Bearing Mice with an mTOR
Inhibitor, CCI-779
We then investigated whether mTOR activity is required
for tumor maintenance in vivo. First, we generated GBMs
from Ntv-a wt mice with the combination of RCAS-KRas and
RCAS-Akt. Mice showing signs of macrocephaly or lethargy
were then screened for GBMs with magnetic resonance
imaging (MRI), which has been previously described [41].
Large tumors were detected by enhancement with intrave-
nous contrast, indicating disruption of the blood–brain bar-
rier. These tumors exhibited histologic characteristics of
human GBMs including pseudopalisading necrosis, pleio-
morphism, and microvascular proliferation. These mice were
chosen because their response to mTOR blockade would
better reflect the therapeutic effects of mTOR inhibitors
on human GBMs. Five mice with GBMs were treated with
CCI-779, a rapamycin analog, through intraperitoneal injec-
tion. Although 0.1 mg/kg per day is the biologic active dose
for xenograft tumors [28], the dose of CCI-779 required to
affect its target in the mouse brain varies and is much higher.
The biologic active doses in the cerebellum and hippocam-
pus are 25 and 10 mg/kg per day, respectively [28,42]. We
therefore chose a daily dose of 40 mg/kg to ensure the inhi-
bition of mTOR activity in mouseGBMs. Because of the large
size of these tumors at the onset of treatment, the mice
survived for 2 to 7 days and the brains were analyzed.
Two of these mice survived for 7 days and could be
reimaged. The MRI results showed that the original contrast
enhancement was reduced, suggesting that the tumor biology
was affectedbyCCI-779 (Figure 5A). Thehistologic analysis of
these tumors showed two effects: regional tumor cell death
and morphologic conversion of surviving tumor cells.
mTOR Blockade Leads to a Subset of Tumor Cells
Undergoing Apoptosis
One mouse became morbid after 48-hour treatment and
was sacrificed. Within this tumor, there were sheets of dead
tumor cells with picnotic nuclei, in contrast to psudopalisad-
ing necrosis in the untreated tumor (Figure 5B). Seven-day
treatment in the other four mice resulted in a similar regional
tumor cell death or dramatic killing of tumor cells.
To assess the effect of CCI-779 on these tumors, adjacent
brain sections were immunostained with HA and P-S6 anti-
bodies. In the untreated GBMs, most tumor cells express
variable amounts of activated Akt (HA positive), and P-S6
levels correlates with activated Akt (Figure 4, A, B, E, and F ).
The reason for this observed variability in untreated GBMs is
unknown, but may partly be due to the oligoclonal nature of
gliomas generated by RACS vector infection. However, the
brain analyzed after a 48-hour treatment showed more exten-
sive cell death surrounded by surviving HA-positive tumor
cells; immunostaining for P-S6 was markedly reduced in the
majority of HA-positive tumor cells. In the brain treated for only
48 hours, some surviving HA-positive tumor cells were also
positive for P-S6, possibly because the drug had not effectively
inhibitedmTORactivity in these regions (Figure 4,C andG). In
contrast, 7-day treatment led to nearly complete loss of P-S6 in
the surviving tumor cells that were positive for HA (Figure 4, D
and H). The lack of correlation between HA and P-S6 staining
in these tumors treated for 7 days is consistent with blockade of
mTOR activity.
Given the appearance of cell death on mTOR blockade in
the GBMs, we performed "TdT - mediated dUTP nick end
labeling (TUNEL) assays to determine whether those cells
underwent apoptosis. Indeed, the areas of cell death were
strongly positive for TUNEL, implying apoptosis occurring
in a subset of the tumor cells within as early as 48 hours
Figure 4. mTOR activity correlates with activated Akt in Akt+KRas– induced GBMs, and mTOR blockade by CCI-779 decreases P-S6 in the surviving tumor
cells. (10) IHC for HA (representing P-Akt) (A and B) and P-S6 (E and F) on adjacent sections from Akt+KRas– induced GBMs suggests that mTOR activity
as measured by P-S6 correlates with activated Akt. (C and G) (10) IHC of HA and P-S6 on adjacent sections from the Akt+KRas– induced GBM treated with
CCI-779 for 48 hours. (D and H) (10) IHC of HA and P-S6 on adjacent sections from the Akt+KRas– induced GBMs treated with CCI-779 for 7 days.
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(Figure 5C, lower panel; Figure 5D). In contrast, there were
few endogenous apoptotic cells in the untreated GBMs, and
these cells weremostly near necrotic areas (Figure 5C, upper
panel ). These results provide evidence that mTOR blockade
resulted in regional apoptosis in the tumor cells. As the
surviving tumor cells after 7-day mTOR blockade express a
relatively lower amount of HA (Figure 4D), it is possible that
CCI-779 treatment resulted in regional killing of GBM cells
expressing high levels of Akt activity, and that GBM cells with
low levels of Akt activity survived mTOR inhibition.
mTOR Blockade Results in Conversion of Surviving GBM
Cells to an Oligodendroglioma-Like Morphology
Astrocytomas are thought to arise from astrocytes or their
precursors, and express an astrocytic marker, GFAP [43].
GBMs are the most malignant subtype of astrocytoma and
maintain the astrocytic character. KRas+Akt–induced GBMs
exhibit typical characteristics of human GBMs [8]. These un-
treated mouse tumor cells have heterogeneously elongated
nuclei and fibrillary cytology. However, in three of four GBMs
that were treated with CCI-779 for 7 days, we observed that
the vast majority of surviving tumor cells was of a different
morphology. Some regions of the surviving tumor cells in one
GBM treated for 7 days also showed a similarly changed
morphology. All those tumor cells consisted of homogenous,
round nuclei surrounded by cleared cytoplasm (Figure 6A,
lower left panel ). In addition, the tumors showed perineuro-
nal satellitosis and perivascular satellitosis in areas of corti-
cal invasion (data not shown). These features resemble the
histologic characteristics of PDGF-induced murine oligoden-
drogliomas [44], which have been shown to contain low Akt
activity. To evaluate the shifted tumor morphology at mo-
lecular level, we performed immunohistochemistry using an
antibody for Olig2, a lineage marker for neural progenitors
and oligodendrocytes that is uniformly expressed in a high
percentage of oligodendroglioma cells [45,46]. Seventy-five
to 85% of the surviving cells in the three GBMs that exhibited
massive morphologic change were strongly positive for
Olig2. In contrast, analysis of untreated GBMs revealed that
less than 10% of cells in the tumors were Olig2-positive and
that their distribution was very heterogeneous (Figure 6, A
and C; Supplementary Figure 1). Although one 7-day–
treated GBM exhibited only partially changed glioma mor-
phology and approximately, 23% of the surviving cells were
Olig2-positive; typical oligodendroglioma morphology was
exclusively seen in the GBMs treated for 7 days but not in
the untreated ones. Overall, the percentage of Olig2-positive
cells in the 7-day–treated GBMs was statistically significant
compared to that of the untreated GBMs (P < .01). The
surviving tumor cells were negative for other oligodendroglial
markers, including A2B5, O4, MBP, and PLP (data not
shown), with the exception that a small percentage of treated
tumor cells were positive for CNPase. This result is consis-
tent with the fact that none of these markers stains human
oligodendrogliomas either [47]. Similar to oligodendroglio-
mas, the tumor cells with shifted morphology in the treated
GBMs were immunonegative for GFAP, except for the
scattered entrapped reactive astrocytes (Figure 6A). Taken
together, both morphologic and immunohistochemical simi-
larities indicate that the surviving GBM cells are converted to
oligodendroglioma cells. However, the GBM treated with
CCI-779 for only 48 hours showed astrocytic morphology
and low Olig2 staining consistent with the above-mentioned
residual S6 activity in these cells (data not shown). It is
Figure 5. mTOR blockade induces apoptotic death in GBM cells expressing
activated Akt. (A) MRI with contrast enhancement images shows loss of
enhancement in a mice bearing GBM after 7-day CCI-779 treatment. (B)
(40) H&E–stained sections demonstrate that in contrast to psudopalisading
necrosis in the untreated GBMs (left panel), 48-hour CCI-779 treatment
resulted in apoptotic cell death in the tumor (right panel). The asterisk
indicates one representative area of pseudopalisading necrosis. (C) (10)
TUNEL assay shows that CCI-779 treatment led to regional apoptotic cell
death (brown color). (D) (400) Higher magnification of the TUNEL assay
results from a mouse GBM treated with CCI-779 for 7 days.
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possible that 48 hours is insufficient to achieve complete
mTOR blockade andmorphologic conversion in the surviving
tumor cells.
There are two potential explanations for the conversion
of morphology for the tumor cell population. First, the low per-
centage of Olig2-positive cells may not have been affected
by CCI-779, and thus their population expanded during the
week of treatment. Second, it is also possible that the sur-
viving tumor cells were dependent on mTOR for maintaining
astrocytic character. Thus, rather than undergoing apopto-
sis, they changed their morphology on mTOR inhibition. To
distinguish between these two possibilities, we performed
immunohistochemistry with a proliferation marker Ki-67 anti-
body to determine if the cells with oligodendrocyticmorphology
were proliferating and capable of giving rise to the residual
tumor mass. We found that in contrast to the untreated GBM
cells, proliferationwas significantly inhibited in surviving cells of
GBMs treated with CCI-779 (Figure 6B), suggesting that
surviving tumor cells acutely converted their morphology and
that mTOR is required to maintain their astrocytic character.
Akt activity shifts KRas-induced nonastrocytic sarcomas
in an Ink4a-Arf–deficient background to an astrocytic GBM
Figure 6.mTOR blockade converts surviving tumor cells to an oligodendroglioma-like morphology (A) (400) Histology comparison of untreated (upper panel) and
7-day– treated GBMs (lower panel) induced by Akt+KRas. Untreated GBM cells showed fibrillary cytology; they were positive for GFAP but most of them were
negative for Olig2, as indicated by H&E and IHC. In contrast, surviving tumor cells acquired oligodendroglioma morphology with round nuclei and cleared
cytoplasm; GFAP-positive cells were reactive astrocytes; and most of the tumor cells were positive for Olig2. (B) (400) IHC of Ki-67 in the untreated (left panel)
and 7-day– treated GBMs shows that mTOR blockade inhibited proliferation of the surviving tumor cells. (C) Percentage of Olig2-positive cells in 7-day– treated
GBMs was much higher than that in the untreated tumors (P < .01). Each symbol represents one tumor, and ‘‘ – ’’ represents the mean value for each tumor group.
(D) mTOR inhibition decreases GFAP protein level in primary astrocytes. Selected primary astrocytes from Gtv-a wt mice were treated with 10 BM LY294002 (LY)
or 10 nM rapamycin (R) for 6 days. After 6 days, cells treated with inhibitors were cultured in medium without inhibitors for an additional 6 days (+/LY, +/R). The
control cells were mocked-treated for 6 days (lane 1) or 12 days (lane 4). Western blot analysis shows that LY294002 inhibited P-Akt and P-S6, and that rapamycin
inhibited P-S6, but the inhibitors did not affect P-Erk significantly. LY294002 and rapamycin inhibited GFAP protein to a similar level, whereas astrocytes began to
express GFAP after removal of the inhibitors.
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morphology [32]. Previous data from our laboratory have
shown that activity of the Akt pathway is not elevated in
PDGF-induced oligodendrogliomas and that addition of ac-
tivated Akt converts PDGF-induced oligodendrogliomas to
astrocytomas. These data imply that elevated Akt activity
plays an important role in astrocytic differentiation of glioma
cells. Moreover, the above results from mTOR inhibition in
the astrocytic GBMs suggest that Akt signaling in astrocytic
differentiation is achieved through mTOR. We therefore
further tested this hypothesis with an in vitro cell culture
experiment. Primary brain cells were prepared from Gtv-a
wt mice and infected with RCAS-puro virus. Astrocytes
were selected with puromycin and then treated with 10 mM
LY294002, a PI3K inhibitor, or 10 nM rapamycin for 6 days.
We observed a decrease in cellular processes on treatment
(data not shown). PI3K inhibition with LY294002 and mTOR
inhibition with rapamycin decreased GFAP protein to similar
levels, suggesting that the GFAP inhibition by LY294002
is mainly through mTOR blockade (Figure 6C, left three
lanes). The inhibition was not due to cell death because after
the inhibitors were removed and cells were allowed to re-
cover for an additional 6 days, they began to reexpressGFAP
(Figure 6C, right three lanes). These results further support
the idea that mTOR is required to maintain the astrocytic
character of glial cells.
To determine if the effect we were seeing could have
parallels in cultured primary brain cells, we measured protein
levels of other oligodendrocytic markers including Olig2,
A2B5, O4, CNPase, MBP, and PLP as a function of mTOR
blockade by Western blot analysis. None of these markers
was detectable in the control-treated or inhibitor-treated
primary astrocyte cultures. The data imply that mTOR activ-
ity may not regulate the conversion of one glial lineage to
another even though it does regulate the conversion of
glioma subtypes. Therefore, these glioma subtypes may
not simply be transformed versions of oligodendrocytes
and astrocytes.
Discussion
GBM is a genetically complex disease. Upstream growth
factor receptor activation and loss of PTEN function both
lead to activation of the AKT signaling pathway, which has
been shown to be causal in gliomagenesis. In human GBMs,
disregulation in PTEN, but not AKT, is seen. The early
embryonic lethality of Pten/ mice has precluded further
studies of the role of Pten loss in GBM formation [13–15].
Here, we recapitulate the genetic aberration seen in human
GBMs and demonstrate that loss of Pten function is similar to
hyperactivated Akt in gliomagenesis. Consistent with our
previous study of Akt in tumorigenesis, Pten loss alone is
insufficient to cause GBMs from neural progenitors, or from
progenitors deficient for Ink4a-Arf. KRas combined with loss
of Pten function leads to GBM formation from neural pro-
genitors, but not from differentiated astrocytes. The tumor
incidence and morphology of the KRas+Pten loss– induced
GBMs are similar to KRas+Akt– induced GBMs. These
results demonstrate the relationship between Pten loss and
Akt in two ways. First, it suggests that much of the oncogenic
effect of Pten loss appears to be due to Akt activity. Second,
it indicates that, at least in culture, Pten loss alone is
sufficient to elevate Akt to oncogenic levels without activation
of upstream growth factor signaling. The mouse studies
imply that AKT and its downstream effectors could be critical
therapeutic targets for treatment of PTEN/ GBMs. Al-
though PTENmutation or deletion is a frequent genetic event
found in human GBMs, our studies suggest that disregula-
tion of the gene alone appears to be insufficient to cause
GBM formation. This observation is supported by data from
other research groups, which showed that inactivation of
Pten in neural progenitors or granule neurons of the dentate
gyrus and cerebellum could not elicit neoplastic transforma-
tion in the brain [48–50]. Moreover, in our study, neural pro-
genitors deficient for both Pten and Ink4a-Arf do not give
rise to GBMs, suggesting that additional genetic alterations
are required for tumor formation in this context.
Many studies have been focused on PTEN as an antag-
onist of PI3K/AKT signaling pathway. Although PTEN may
have other functions, such as downregulation of MAPK
pathway through dephosphorylation of SHC [35,36], our
in vitro experiment suggests that this is not occurring in glial
cells. Pten has also been shown to inhibit tumor invasion
independent of its lipid phosphatase activity [51], or possibly
through dephosphorylation of FAK [34]. In addition, Pten can
regulate p53 protein levels and activity through phosphatase-
independent mechanisms [52]. In fact, some GBMs
harbor PTEN mutations outside the sequences encoding
the phosphatase domain, which may not affect its phos-
phatase activity [53]. Our data suggest that although these
functions may be occurring, they appear not to be required
for gliomagenesis.
There is emerging evidence suggesting that mTOR is a
critical downstream component in PTEN/AKT signaling pos-
itively regulating cell growth and survival [54,55]. mTOR has
also been implicated as an indirect homeostatic sensor for
nutrients and ATP [56]. We demonstrate here that mTOR
activity correlates with activated Akt in the mouse GBMs.
Within these tumors, the cells expressed virally encoded Akt
heterogeneously, potentially due to the oligoclonal nature of
RCAS-induced tumors. The tumor cells with elevated Akt
appear to be dependent on mTOR for survival, and mTOR
blockade in these cells leads to apoptotic cell death. This
cytotoxic effect is also seen in a recent study showing that
mTOR inhibition in Akt-dependent murine prostate intra-
epithelial neoplasia induces apoptosis and complete rever-
sion of the neoplastic phenotype [57]. In our experiments,
mTOR inhibition did not result in killing of all tumor cells;
those with lower active Akt expression survived and changed
morphology associated with loss of mTOR activity as mea-
sured by phosphorylation of S6.
mTOR inhibitors, including CCI-779, rapamycin, and
RAD001, have been disappointing as single agents in clinical
trials for GBM patients. Several explanations might account
for the different responses in mouse and human studies.
First, these patients have not been stratified by AKT activity
prior to enrolling them into these trials. Second, the daily
364 The Pten loss/Akt/mTOR signaling in mouse GBMs Hu et al.
Neoplasia . Vol. 7, No. 4, 2005
treatment regimen in mice may be more effective in blocking
mTOR activity relative to weekly CCI-779 administration in
patients. Third, a few GBM patients have, in fact, shown
response to rapamycin treatment; our mouse model may
reflect the biologic status of this subset of tumors. Finally,
human GBM often harbors multiple genetic alterations; it is
possible that in the presence of other genetic alterations (not
present in themouse tumors), mTOR is not required for tumor
maintenance. Using our genetically simplified Ras+Akt
mouse GBM model, mTOR inhibition does not result in
complete tumor remission. Studies from Akt-driven lympho-
mas demonstrated that although mTOR blockade only leads
to partial response, it greatly enhances the sensitivity of
tumor cells to chemotherapy [58]. Therefore, ourmouse data,
together with those of others, suggest that inhibition of
multiple signaling pathways, in combination with chemother-
apy, might be necessary for therapeutic success in human
GBM management.
Our previous studies showed that Akt causes astrocytic
differentiation in glioma cells [32]. In the Akt+KRas–induced
GBMs treated with CCI-779, surviving cells acquired an
oligodendroglioma-like morphology. We demonstrate that
CCI-779 inhibits proliferation of these cells and the conver-
sion from astrocytic to oligodendrocytic character. The sur-
viving cells had lower Akt activity, suggesting that although
they are not dependent on mTOR for maintenance, they do
require mTOR to maintain astrocytic differentiation.
Several studies have proposed the existence of cancer
stem cells in certain central nervous system (CNS) tumors,
including gliomas [59–61]. These tumors have been pro-
posed to derive from stem cells or glial-restricted progenitors
with accumulation of mutations, and are capable of self-
renewing, proliferating, and giving rise to cells of multiple line-
ages. Previous mouse studies from our laboratory have
demonstrated that both activation of signaling pathways
and the cell of origin are important for glioma formation and
histologic character. In this system, gliomas can arise in
mice from either neural progenitors or astrocytes [8,32,44],
although nestin-expressing progenitors are far more sensi-
tive to the oncogenic effects of Ras and Akt signaling. The
morphology of these gliomas can also be changed by the
activity of signaling pathways [32]. Here we demonstrate
a transition between the two glioma subtypes induced by
mTOR inhibition. This effect appears to not result from
expansion of a clonal cell population, but rather from con-
version of tumor cell morphology. This observed shift from
one apparent glial lineage to another further provides evi-
dence to support an alternative possibility that the exis-
tence of tumors apparently containing multiple lineages
may reflect regional signaling pathway activity rather than
necessarily arising from a stem-like cell of origin.
Experimental Procedures
Mice
Generation of the PtenloxP/loxP (LP ) mice has been de-
scribed previously, and their genetic background was a
mixture of 129/Sv, CJ7, and C57BL6/J [37]. Production of
the Ntv-a wt, Gtv-a wt, and Ntv-a Ink4a-Arf/ mouse lines
has been described [38]. The resulting genetic backgrounds
of tv-a transgenic mice were a mixture of FVB/N, C57BL6,
BALB/C, and 129. LP mice were mated with tv-a transgenic
mice to produce homozygous Ntv-a LP, Gtv-a LP, and Ntv-a
Ink4a-Arf/ LP mice. Screening of tv-a, LP, and Ink4a-Arf
alleles has been described [37,38].
RCAS Plasmids
RCAS-GFPCre was made by fusing EGFP and Cre and
by cloning the fusion gene into the Not1 site of the RCAS-Y
vector [62]. We confirmed that the fusion protein expressed
from viruses emits fluorescence and can mediate the recom-
bination of loxP sites using cultured cell in the presence of a
Cre reporter construct CLLA that expresses a floxed LacZ
followed by alkaline phosphatase (unpublished). RCAS-
LacZ plasmid was described previously [44]. RCAS-Akt
carries the activated form of designated Akt-Myr D11-60
and has a HA tag sequence added to the 3V-end of the
cDNA. It was a gift from Peter Vogt (The Scripps Research
Institute, La Jolla, CA). RCAS-KRas (G12D) plasmid was
kindly provided by Galen Fisher (Medical University of South
Carolina, Charleston, SC).
Infection of Primary Brain Cell Culture
Primary brain cells from newborn tv-a transgenic mice
were cultured in DMEMwith 10% FBS (Gemini) as described
before [44]. The supernatants containing various RCAS
virons from DF-1 cells transfected with various RCAS plas-
mids were collected and filtered through 0.22-mm filters,
followed by transferring into 70% to 80% confluent primary
brain cell cultures. Infections were repeated three times with
12-hour intervals. For selection of primary astrocytes, pri-
mary brain cells from Gtv-a wt mice were infected with
RCAS-puro virus and then selected in 4 mg/ml puromycin
(Sigma, St. Louis, MO).
Blocking of PI3K and mTOR Signaling in Cell Culture
Selected primary astrocytes were treated with 10 mM
LY294002 (stock dissolved in DMSO; Cell Signaling,
Beverly, MA) or 10 nM rapamycin (stock dissolved in meth-
anol; Sigma, St. Louis, MO) for 6 days. Fresh medium with
the inhibitors was added every 24 hours. After 6 days, two
groups of cells treated with inhibitors were cultured in me-
dium without inhibitors for an additional 6 days. The control
groups were treated with the same volumes of DMSO and
methanol for 6 or 12 days.
PCR Analysis
DNA was extracted from primary Ntv-a LP brain cells
infected with RCAS viruses or the tail of a Ntv-a LP +/
mouse, and subjected to PCR analysis using primer 1 (5V-
AAAAGTTCCCCTGCTGATGATTTGT-3V), primer 2 (5V-
TGTTTTTGACCAATTAAAGTAGGCTGTG-3V), and primer
3 (5V-CCCCCAAGTCAATTGTTAGGTCTGT-3V). PCR con-
ditions were 95jC, 5 minutes; 95jC, 30 seconds; 55jC,
1 minute; 72jC, 1 minute for 35 cycles using puRe Taq
Ready-To-Go PCR Beads (Amersham, Piscataway, NJ).
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Western Blot Analysis
Whole cell lysates were dissolved in cold lysis buffer
[mammalian protein extraction reagent (M-PER; Pierce,
Rockford, IL), 100 mM NaCl, 30 mM NaF, 1mM EDTA, 0.5
mM PMSF, 1 mM Na3VO4, and protease inhibitor cocktail
tablets (Roche, Indianapolis, IN)] for 30 minutes on ice,
followed by centrifugation. Protein concentration was mea-
sured by the BCA method (Pierce). Fifty micrograms of
protein samples was separated by 10% SDS-PAGE electro-
phoresis and transferred to PVDF membranes. Membranes
were blocked with 5% nonfat milk in phosphate-buffered
saline (PBS; pH 7.4) with 0.1% Tween 20. Primary and
secondary antibodies were diluted in the same solution.
Signals were visualized by ECL chemiluminescence (Amer-
sham) or supersignal chemiluminescence (Pierce). PTEN
1:600 (Cascade, Winchester, MA), P-Akt (Ser473), P-Erk
(Ser217/221), Akt and Erk 1:1000 (Cell Signaling), GFAP
1:100 (Santa Cruz Biotechnology, Santa Cruz, CA), GAPDH
1:1000 (Advanced ImmunoChemical, Long Beach, CA),
antirabbit HRP 1:1000 (Amersham), and antimouse IgG+IgM
HRP and antigoat IgG+IgM HRP 1:1000 (Roche) were used.
Infection of Transgenic Mice
DF-1 cells producing various RCAS virons were trypsi-
nized and pelleted by centrifugation. The pellets were resus-
pended in approximate 50 ml of medium and placed on ice.
Using a 10-ml Hamilton syringe, a single intracranial injection
of 1 ml containing 104 cells was made in the right frontal
region of newborn mice. Statistical analysis was performed
with the GraphPad software Prism3 using the log-rank test
applied to Kaplan-Meier graphs.
Brain Sectioning, H&E Staining, and Immunohistochemistry
Mice were sacrificed before (due to symptoms of hydro-
cephalus or lethargy), or at 12 weeks of age. The whole
brains were fixed, paraffin-embedded, and processed as
previously described [8]. The sections were stained with
H&E. As for IHC, slides were stained with primary antibody
overnight at 4jC. Immunohistochemistry detection was per-
formed with the ABC kit (Vector Laboratories, Burlingame,
CA). PTEN 1:300 (ABM2051; Cascade), HA 1:200 (Y-11;
Santa Cruz Biotechnology), P-Erk 1:50 (9101; Cell Signal-
ing), P-S6 1:50 (2211; Cell Signaling), PCNA 1:500
(MAB424R; Chemicon), GFAP 1:1000 (MAB3402; Chemi-
con, Temecula, CA), nestin 1:200 (556309; PharMingen,
San Diego, CA), and Ki-67 1:500 (Novacastra, Newcastle
upon Tyne, UK) were used. Olig2 is a gift from John Albeta
(Dana-Farber Cancer Institute, Boston, MA).
Treatment of GBM-Bearing Mice
Symptomatic mice were anesthesized with isoflurane and
scanned with MRI. For contrast enhancement, mice were
intravenously administered 0.2 mM/kg gadolinium diethyle-
netramine pentaacetic acid. Images were obtained as previ-
ously described [41]. Mice with enhancement were treated
with CCI-779 (Wyeth, Pearl River, NY) through intraperito-
neal injection daily at a dose of 40 mg/kg. The drug was first
dissolved to 50 mg/ml in 100% ethanol and then diluted to
2 mg/ml with 5% Tween-80 (Sigma) and 5% polyethylene
glycol-400 (Sigma).
Analysis of Olig2-Positive Tumor Cells
The percentage of packed Olig2-positive cell area in the
entire untreated and treated GBMs was independently
scored by three individuals, followed by averaging the num-
bers for corresponding GBMs. For each GBM, the average
ratio of Olig2-positive cells in the packed area was obtained
by counting Olig2-positive and total cells within the tumors in
five random microscopic views of 400. The ultimate per-
centage of Olig2-positive cells in the tumors was calculated
by multiplying the average percentage of packed Olig2-
positive cell area and the average percentage of the ratio
of Olig2-positive cells. A two-tailed t-test was used to eval-
uate the significance of the difference of Olig2-positive cells
between the untreated and 7-day–treated GBMs.
TUNEL Assay
Deparaffinized slides were incubated with 20 mg/ml pro-
teinase K for 20 minutes at room temperature, followed by
fixation in 4% paraformaldehyde for 10 minutes at room
temperature. Endogenous peroxidase was inactivated by
0.1% hydrogen peroxide in PBS. The sections were incu-
bated with TUNEL dilution buffer (Roche), and then with the
same buffer containing biotin-dUTP (Roche) and terminal
deoxynucleotidyl transferase (Roche) for 1 hour at 37jC.
The reaction was stopped by immersing the slides into 2
SSC (Sigma), and staining was performed using ABC kits
(Vector Laboratories).
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